References
Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., & Walter, P. (2002). Molecular biology of the cell (4th ed.). New York: Garland Science.
Alvarez-Secord, A., Sayer, R., Snyder, S. A., Broadwater, G., Rodriguez, G. C., Berchuck, A., et al. (2004). The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer. Gynecologic Oncology, 94(1), 74-79.
Auersperg, N., Ota, T., & Mitchelle, G. W. (2002). Early events in ovarian epithelial carcinogenesis: Progress and problems in experimental approaches. International Journal of Gynecologic Cancer, 12(6), 691-703.
Aunoble, B., Sanches, R., Didier, E., & Bignon, Y. J. (2000). Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer. International Journal of Oncology, 16(3), 567-576.
Candido Dos Reis, F. J., Moreira de Andrade, J., & Bighetti, S. (2002). CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors. Gynecologic and Obstetric Investigation, 54(3), 132-136.
Chin, D., Boyle, G. M., Parsons, P. G., & Coman, W. B. (2004). What is transforming growth factor-beta (TGF-beta)? British Journal of Plastic Surgery, 57(3), 215-221.
Cirisano, F. D., & Karlan, B. Y. (1996). The role of the HER-2/neu oncogene in gynecologic cancers. Journal of the Society for Gynecologic Investigation, 3(3), 99-105.
Counter, C. M., Hirte, H. W., Bacchetti, S., & Harley, C. B. (1994). Telomerase activity in human ovarian carcinoma. Proceedings of the National Academy of Sciences, 91(8), 2900-2904.
Evan, G., & Littlewood, T. (1998). A matter of life and cell death. Science, 281(5381), 1317-1322.
Faleiro-Rodrigues, C., Macedo-Pinto, I., Pereira, D., Ferreira, V. M., & Lopes, C. S. (2004). Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas. Human Pathology, 35(6), 663-669.
Fraser, M., Leung, B., Jahani-Asl, A., Yan, X., Thompson, W. E., & Tsang, B. K. (2003). Chemoresistance in human ovarian cancer: The role of apoptotic regulators. Reproductive Biology and Endocrinology, 1, 66.
Fujita, M., Enomoto, T., & Murata, Y. (2003). Genetic alterations in ovarian carcinoma: With specific reference to histological subtypes. Molecular and Cellular Endocrinology, 202(1-2), 97-99.
Hahn, W. C., & Weinberg, R. A. (2002). Rules for making human tumor cells. New England Journal of Medicine, 347(20), 1593-1603.
Hanahan, D., & Weinberg, R. A. (2000). The hallmarks of cancer. Cell, 100(1), 57-70.
Hazelton, D., Nicosia, R. F., & Nicosia, S. V. (1999). Vascular endothelial growth factor levels in ovarian cyst fluid correlate with malignancy. Clinical Cancer Research, 5(4), 823-829.
Hsieh, C. Y., Chen, C. A., Chou, C. H., Lai, K. P., Jeng, Y. M., Kuo, M. L., et al. (2004). Overexpression of Her-2/NEU in epithelial ovarian carcinoma induces vascular endothelial growth factor C by activating NF-kappa/B: Implications for malignant ascites formation and tumor lymphangiogenesis. Journal of Biomedical Science, 11(2), 249-259.
Jacobs, I., & Bast, R. C., Jr. (1989). The CA 125 tumour-associated antigen: A review of the literature. Human Reproduction, 4(1), 1-12.
Kabawat, S. E., Bast, R. C., Welch, W. R., Knapp, R. C., & Colvin, R. B. (1983). Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid and clear cell types. American Journal of Clinical Pathologists, 79(1), 98-104.
Kafali, H., Artunc, H., & Erdem, M. (2007). Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle. Archives of Gynecology and Obstetrics, 275(3), 175-177.
Kan, Y. Y., Yeh, S. H., Ng, H. T., & Lou, C. M. (1992). Effect of menstruation on serum CA125 levels. Asia Oceania Journal of Obstetrics and Gynaecology, 18(4), 339-343.
Kenemans, P., van Kamp, G. J., Oehr, P., & Verstraeten, R. A. (1993). Heterologous double-determinant immunoradiometric assay CA 125 II: Reliable second-generation immunoassay for determining CA125 in serum. Clinical Chemistry, 39(12), 2509-2513.
King, R. C., & Stansfield, W. D. (2002). A dictionary of genetics. New York: Oxford University Press.
Kui Wong, N., Easton, R. L., Panico, M., Sutton-Smith, M., Morrison, J. C., Lattanzio, F. A., et al. (2003). Characterization of the oligosaccharides associated with the human ovarian tumor marker CA125. Journal of Biological Chemistry, 278(31), 28619-28634.
Matias-Guiu, X., & Prat, J. (1998). Molecular pathology of ovarian carcinomas. Virchows Archiv, 433(2), 103-111.
Meden, H., & Kuhn, W. (1997). Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: A new prognostic factor. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 71(2), 173-179.
Meden, H., Marx, D., Fattahi, A., Rath, W., Kron, M., Wuttke, W., et al. (1994). Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy. Journal of Cancer Research and Clinical Oncology, 120(6), 378-381.
Mukhopadhyay, D., & Datta, K. (2004). Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Seminars in Cancer Biology, 14(2), 123-130.
Nussbaum, R. L., McInnes, R. R., Willard, H. F. (Eds.). (2001). Thompson and Thompson genetics in medicine (6th ed.). Philadelphia: Saunders.
Nustad, K., Onsrud, M., Jannson, B., & Warren, D. (1998). CA125-epitopes and molecular size. International Journal of Biological Markers, 13(4), 196-199.
Ribatti, D. (2005). The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: A historical review. British Journal of Haematology, 128(3), 303-309.
Robertson, D. M., Pruysers, E., Burger, H. G., Jobling, T., McNeilage, J., & Healy, D. (2004). Inhibins and ovarian cancer. Molecular and Cellular Endocrinology, 225(1-2), 65-71.
Roskelley, C. D., & Bissell, M. J. (2002). The dominance of the microenvironment in breast and ovarian cancer. Seminars in Cancer Biology, 12(2), 97-104.
Rubin, S. C., & Sutton, G. P. (2004). Ovarian cancer (2nd ed.). Philadelphia: Lippincott Williams and Wilkins.
Seelenmeyer, C., Wegehingel, S., Lechner, J., & Nickel, W. (2003). The cancer antigen CA125 represents a novel counter receptor for galectin-1. Journal of Cell Science, 116(Pt. 7), 1305-1318.
Shayesteh, L., Lu, Y., Kuo, W. L., Baldocchi, R., Godfrey, T., Collins, C., et al. (1999). PIK3CA is implicated as an oncogene in ovarian cancer. Nature Genetics, 21(1), 99-102.
Sonmezer, M., Gungor, M., Ensari, A., & Ortac, F. (2004). Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: In association with transforming growth factor beta and vascular endothelial growth factor. International Journal of Gynecological Cancer, 14(1), 82-88.
Sorak, M., Arsenijevic, S., Lukic, G., Arsenijevic, N., Ristic, P., Pavlovic, S., et al. (2007). Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma. Journal of the Balkan Union of Oncology, 12(1), 99-104.
Sun, P. M., Wei, L. H., Luo, M. Y., Liu, G., Wang, J. L., & Mustea, A. (2007). The telomerase activity and expression of hTERT gene can serve as indicators in the anti-cancer treatment of human ovarian cancer. European Journal of Obstetrics, Gynecology, and Reproductive Biology, 130, 249-257.
Sundfeldt, K. (2003). Cell-cell adhesion in the normal ovary and ovarian tumors of epithelial origin; an exception to the rule. Molecular and Cellular Endocrinology, 202(1-2), 89-96.
Tammela, T., Enholm, B., Alitalo, K., & Paavonen, K. (2005).The biology of vascular endothelial growth factors. Cardiovascular Research, 65(3), 550-563.
Tannock, I. F., Hill, R. P., Bristow, R. G., & Harrington, L. (2005). The basic science of oncology (4th ed.). San Francisco: McGraw-Hill.
Tong, S., Wallace, E. M., & Burger, H. G. (2003). Inhibins and activins: Clinical advances in reproductive medicine. Clinical Endocrinology, 58(2), 115-127.
Verheijen, R. H., von Mensdorff-Pouilly, S., van Kamp, G. J., & Kenemans, P. (1999). CA 125: Fundamental and clinical aspects. Seminars in Cancer Biology, 9(2), 117-124.
Villa, R., Folini, M., Perego, P., Supino, R., Setti, E., Daidone, M. G., et al. (2000). Telomerase activity and telomere length in human ovarian cancer and melanoma cell lines: Correlation with sensitivity to DNA damaging agents. International Journal of Oncology, 16(5), 995-1002.
Wenham, R. M., Lancaster, J. M., & Berchuck, A. (2002). Molecular aspects of ovarian cancer. Best Practice and Research. Clinical Obstetrics and Gynaecology, 16(4), 483-497.
Zhang, L., Yang, N., Katsaros, D., Huang, W., Park, J. W., Fracchioli, S., et al. (2003). The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Research, 63(14), 4225-4231.